Becton, Dickinson and Company (NYSE:BDX) Position Increased by Northcape Wealth Management LLC

Northcape Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,694 shares of the medical instruments supplier’s stock after buying an additional 139 shares during the quarter. Northcape Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $2,337,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 7.4% in the 1st quarter. Kingsview Wealth Management LLC now owns 4,306 shares of the medical instruments supplier’s stock worth $1,065,000 after acquiring an additional 296 shares during the period. Spirepoint Private Client LLC bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $385,000. Cornerstone Advisors LLC boosted its position in shares of Becton, Dickinson and Company by 7.0% during the first quarter. Cornerstone Advisors LLC now owns 7,600 shares of the medical instruments supplier’s stock worth $1,881,000 after buying an additional 500 shares during the period. Acadian Asset Management LLC grew its holdings in Becton, Dickinson and Company by 843.7% in the 1st quarter. Acadian Asset Management LLC now owns 3,237 shares of the medical instruments supplier’s stock worth $799,000 after buying an additional 2,894 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board increased its position in Becton, Dickinson and Company by 3.6% in the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,919,583 shares of the medical instruments supplier’s stock valued at $475,001,000 after acquiring an additional 67,305 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Down 0.9 %

BDX stock opened at $225.15 on Friday. The firm has a market cap of $65.08 billion, a PE ratio of 37.90, a P/E/G ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The firm has a 50 day simple moving average of $236.30 and a 200 day simple moving average of $234.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.42 earnings per share. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.85%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 63.97%.

Analyst Ratings Changes

Several research firms have recently issued reports on BDX. Raymond James decreased their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus increased their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.